focus -WSS

focus

author：focus 2025-09-03 03:39:10 - browse：99211

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Inequities make cancer less preventable for women: report

Wikipedia

WSS

Kaiser Permanente unions announce official strike date

FDA seeks to regulate lab

It was time to plan for my old age. If only I could stop crying

Kaiser Permanente unions announce official strike date

'Brian's Song' at 50 still offers lessons about cancer for today

Sudafed saga points to U.S. issues with evaluating older drugs

hotspot

focus

hotspot

Activists slam private health insurers over coverage restrictions

It was time to plan for my old age. If only I could stop crying

At least 13 dead in Texas as scorching temps continue

Failure, not just success, should guide future doctors

The cancer drug shortage isn’t new — and neither are the solutions

Sudafed saga points to U.S. issues with evaluating older drugs

Alkermes shareholders re

Medicaid, Medicare dual

Trump demands the U.S. pay no more for drugs than other countries … again

Address the ethical violations that led to 'Three Identical Strangers'

Wikipedia

Failure, not just success, should guide future doctors

Would Medicare drug price negotiations stall in a shutdown?

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Listen: Who gets the credit for GLP

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Researchers use wearables data and AI to predict preterm birth risk

Wikipedia

Wikipedia

leisure time

hotspot